The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
aESTEEM 2 study. Data as observed; includes patients who were randomized to OTEZLA 30 mg BID or placebo at baseline, were PASI-50 responders at week 32, and who continued to receive OTEZLA 30 mg BID up to week 52.
bAt week 16, ScPGA score of 0 (clear) or 1 (minimal) achievement was significantly greater with OTEZLA 30 mg BID (40.9%, 72/176) vs placebo (17.2%, 16/93); P < 0.0001; FAS, LOCF.
OTEZLA clears or minimizes scalp psoriasis1
Baseline
Week 16
Individual results may vary.
*Among patients with moderate to very severe scalp psoriasis at baseline (ScPGA score ≥3; n = 269/411, 65.5%).
†Photos taken from the ESTEEM clinical trial program, which evaluated OTEZLA 30 mg BID in patients with active plaque psoriasis.
BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; FAS, full analysis set; LOCF, last observation carried forward; PASI, Psoriasis Area and Severity Index; ScPGA, Scalp Physician Global Assessment.
aLIBERATE study. mITT, LOCF. Includes patients with ScPGA ≥3 (moderate or greater) at baseline. Response at week 16 and week 104 was determined using the LOCF methodology. Week 104 analysis includes patients who entered the apremilast extension phase and were treated in the phase.
bP = 0.0458, OTEZLA vs placebo.
Scalp response was sustained for up to 2 years with OTEZLA3
BID, twice daily; BL, baseline; DLQI, Dermatology Life Quality Index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; VAS, visual analogue scale.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
